Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (HKSE:01349) EV-to-Revenue : 6.00 (As of May. 15, 2024)

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co EV-to-Revenue Chart

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Annual Data
	Trend	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23
EV-to-Revenue		Get a 7-Day Free Trial					3.19	2.41	1.84	1.94	1.47

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Quarterly Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-Revenue	Get a 7-Day Free Trial															3.13	1.02	1.30	1.47	1.04

Competitive Comparison of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's EV-to-Revenue falls into.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's EV-to-Revenue for today is calculated as:

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's current Enterprise Value is HK$5,277.2 Mil.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Revenue for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$880.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co  (HKSE:01349) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's PS Ratiofor today is calculated as:

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's share price for today is HK$2.22.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$0.81.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co (HKSE:01349) Business Description